Morgan Stanley Downgrades Amgen to 'Equal-Weight'

Analyst Caroline Copithorne predicts a tighter limit on the drugmaker's upside to revenue and earnings in future quarters

Morgan Stanley downgraded Amgen (AMGN ) to equal-weight from overweight.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.